A dendritic cell vaccine personalized for each individual based on the patient's own tumor may increase median survival time in those with a deadly form of brain cancer called glioblastoma, an early phase study at UCLA's Jonsson Comprehensive Cancer Center has found.
Published this week in the peer-reviewed journal Clinical Cancer Research, the study also identified a subset of patients more likely to respond to the vaccine, those with a subtype of glioblastoma known as mesenchymal, which accounts for about one-third of all cases. This is the first time in brain cancer that a subset of patients more likely to respond to an immunotherapy has been identified, said Dr. Linda Liau, a Jonsson Cancer Center researcher, professor of neurosurgery and senior author of the study.
The study found that the vaccine, administered after the conventional treatments of surgery and radio-chemotherapy, was associated with a median survival of 31.4 months, double the 15 months of historical controls in the published literature. In all, 23 patients were enrolled in the Phase I study that was launched in 2003. Of those, about one third of participants are still alive, some more than eight years after their diagnosis.
The study also found that the vaccine was safe and that side effects were minimal, limited mostly to flu-like symptoms and rashes near the vaccine injection site.
"This is quite an encouraging result, especially in an early phase study like this," Liau said. "It's promising to see patients with this type of brain cancer experience such long survivals."
However, Liau cautioned that the findings need to be confirmed in larger, randomized studies. She currently is leading a Phase II, randomized study at UCLA testing the vaccine in newly diagnosed glioblastoma patients. The patients will receive either the standard of care (surgery, radiation and chemotherapy) or the standard of care plus the vaccine. The study is
'/>"/>
| Contact: Kim Irwin kirwin@mednet.ucla.edu 310-206-2805 University of California - Los Angeles Source:Eurekalert |
Related biology news :
1. For first time, scientists show an HIV vaccine impacts the genetic makeup of the virus
2. Vaccine made with synthetic gene protects against deadly pneumonia
3. Media advisory -- Partnering to Fight TB: The Role of a TB Vaccine PDP
4. Saint Louis University findings: Dont pitch stockpiled avian flu vaccine
5. Researchers test inhalable measles vaccine
6. Therapeutic AIDS vaccine designed by HIVACAT reduces the viral load in the majority of AIDS patients
7. H1N1 pandemic points to vaccine strategy for multiple flu strains
8. Team creates novel vaccine that produces strong immunity against cocaine high
9. New vaccine to assist worldwide eradication of polio
10. Experts converge at Arizona State University for first preventive cancer vaccine conference
11. Blame the environment: Why vaccines may be ineffective for some people
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |